Laparoscopic radical cystectomy with extracorporeal urinary diversion: an Italian single-center experience with 10-year outcomes

Bada, Maida; Concilio, Bernardino De; Crocetto, Felice; Creta, Massimiliano; Silvestri, Tommaso; Mauro, Marina Di; Celia, Antonio

doi:10.23736/s0393-2249.20.03850-3

Cited by 14 publications

(14 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Intravesical BCG therapy fails in up to 40% of patients with non-muscle-invasive bladder cancer (NMIBC) [1]. Radical cystectomy (RC) represents the 'gold standard' in these patients, but carries significant morbidity [1,2]. Delayed RC is associated with a decreased diseasespecific survival [3].…”

Section: Introductionmentioning

confidence: 99%

Impact of systemic inflammatory markers on the response to Hyperthermic IntraVEsical Chemotherapy (HIVEC) in patients with non-muscle-invasive bladder cancer after bacillus Calmette–Guérin failure

Chiancone

Fabiano

Carrino

et al. 2021

Arab Journal of Urology

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Impact of systemic inflammatory markers on the response to Hyperthermic IntraVEsical Chemotherapy (HIVEC) in patients with non-muscle-invasive bladder cancer after bacillus Calmette–Guérin failure

Chiancone

Fabiano

Carrino

et al. 2021

Arab Journal of Urology

View full text Add to dashboard Cite

show abstract

“…While chemotherapy agents such as mitomycin and gemcitabine (4) can be used for intravesical therapy against non-invasive bladder cancer, intravesical BCG represents the standard therapy for patients with T1 disease (5), and cystectomy (6)(7)(8), with or without perioperative chemotherapy (9), is recommended for muscle-invasive, localized bladder cancer (10). Advances in the field of peri-operative systemic therapy of muscle-invasive bladder cancer have been scarce over the past 20 years.…”

Section: Introductionmentioning

confidence: 99%

Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis

et al. 2021

Self Cite

View full text Add to dashboard Cite

BackgroundThree or four cycles of cisplatin-based chemotherapy is the standard neoadjuvant treatment prior to cystectomy in patients with muscle-invasive bladder cancer. Although NCCN guidelines recommend 4 cycles of cisplatin-gemcitabine, three cycles are also commonly administered in clinical practice. In this multicenter retrospective study, we assessed a large and homogenous cohort of patients with urothelial bladder cancer (UBC) treated with three or four cycles of neoadjuvant cisplatin-gemcitabine followed by radical cystectomy, in order to explore whether three vs. four cycles were associated with different outcomes.MethodsPatients with histologically confirmed muscle-invasive UBC included in this retrospective study had to be treated with either 3 (cohort A) or 4 (cohort B) cycles of cisplatin-gemcitabine as neoadjuvant therapy before undergoing radical cystectomy with lymphadenectomy. Outcomes including pathologic downstaging to non-muscle invasive disease, pathologic complete response (defined as absence of disease -ypT0), overall- and cancer-specific- survival as well as time to recurrence were compared between cohorts A vs. B.ResultsA total of 219 patients treated at 14 different high-volume Institutions were included in this retrospective study. Patients who received 3 (cohort A) vs. 4 (cohort B) cycles of neoadjuvant cisplatin-gemcitabine were 160 (73,1%) vs. 59 (26,9%).At univariate analysis, the number of neoadjuvant cycles was not associated with either pathologic complete response, pathologic downstaging, time to recurrence, cancer specific, and overall survival. Of note, patients in cohort B vs. A showed a worse non-cancer specific overall survival at univariate analysis (HR= 2.53; 95 CI= 1.05 - 6.10; p=0.046), although this finding was not confirmed at multivariate analysis.ConclusionsOur findings suggest that 3 cycles of cisplatin-gemcitabine may be equally effective, with less long-term toxicity, compared to 4 cycles in the neoadjuvant setting.

show abstract

“…In NMIBC, the gold standard treatment contemplates a complete transurethral resection of bladder tumour and the subsequent induction and maintenance cycles with intravesical mitomycin chemotherapy or intravesical Bacille Calmette–Guerin (BCG) immunotherapy (TURBT) ( 5 ). MIBC requires, instead, a multimodal approach to achieve the best chance in terms of prognosis, which comprises different treatments such as neoadjuvant chemotherapy and radical cystectomy with an open, laparoscopic, or robotic approach ( 6 ). It is although possible, in selected MIBC patients, to offer a bladder-sparing alternative, which includes, similarly to NMIBC, transurethral resection followed by chemotherapy and/or radiotherapy ( 5 ).…”

mentioning

confidence: 99%

Lymphocyte to Monocyte Ratio: A New Independent Prognostic Factor in Bladder Cancer Progression?

et al. 2021

Self Cite

View full text Add to dashboard Cite

Laparoscopic radical cystectomy with extracorporeal urinary diversion: an Italian single-center experience with 10-year outcomes

Cited by 14 publications

References 5 publications

Impact of systemic inflammatory markers on the response to Hyperthermic IntraVEsical Chemotherapy (HIVEC) in patients with non-muscle-invasive bladder cancer after bacillus Calmette–Guérin failure

Impact of systemic inflammatory markers on the response to Hyperthermic IntraVEsical Chemotherapy (HIVEC) in patients with non-muscle-invasive bladder cancer after bacillus Calmette–Guérin failure

Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis

Lymphocyte to Monocyte Ratio: A New Independent Prognostic Factor in Bladder Cancer Progression?

Contact Info

Product

Resources

About